Home / Technology & Devices

Technology & Devices

Cara Therapeutics Enters into License Agreement with Enteris BioPharma for Peptelligence Oral Formulation Technology

BOONTON, N.J., Aug. 21, 2019 /PRNewswire/ — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, today announced its entry into a definitive licensing agreement with Cara Therapeutics (Nasdaq: CARA) for Enteris’ Peptelligence® technology in the ongoing development of an oral …

Read More »

CVRx Receives FDA Approval for World’s First Heart Failure Neuromodulation Device

MINNEAPOLIS, Aug. 16, 2019 /PRNewswire/ — CVRx, Inc., a private medical device company, announced today that it has received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO device for heart failure in the United States. The FDA’s Center for Devices and …

Read More »

Agilent Technologies Introduces Revolutionary Real-Time Cell Analyzer

Agilent Technologies Inc. (NYSE: A) today introduced a multimode real-time cell analyzer (RTCA)—the first of its kind—combining the best of non-invasive biosensor measurement with live cell imaging.  “The xCELLigence RTCA eSight will revolutionize cell analysis in life science research,” said Todd Christian, Agilent vice president, and general manager of the company’s Cell …

Read More »

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Ingelheim, Germany, 12 August 2019 – Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development …

Read More »

Siemens to Acquire Corindus Vascular Robotics for $1.1 Billion

WALTHAM, Mass., — August 8, 2019 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens …

Read More »

Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ — Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may be able to differentiate …

Read More »

NORD and C-Path to Launch FDA-Funded Rare Disease Data Analytics Platform

TUCSON, Ariz. and WASHINGTON, Aug. 7, 2019 /PRNewswire/ — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders® (NORD) will host a meeting on Tuesday, September 17 in Bethesda, MD to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative …

Read More »

REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich’s Ataxia Using NAV AAV9 Vector

ROCKVILLE, Md., July 31, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc. Under the terms of the …

Read More »

Exact Sciences and Genomic Health Combine to Create a Leading Global Cancer Diagnostics Company

MADISON, Wis. and REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS) and Genomic Health, Inc. (NASDAQ: GHDX) today announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and …

Read More »

REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases

ROCKVILLE, Md., July 24, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an expansion of its pipeline to include novel treatments for hereditary angioedema (HAE) and …

Read More »